

Alexandre Vivot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2050885/publications.pdf>

Version: 2024-02-01

28
papers

811
citations

623734

14
h-index

501196

28
g-index

31
all docs

31
docs citations

31
times ranked

1775
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000â€“2015. <i>Annals of Oncology</i> , 2017, 28, 1111-1116.	1.2	102
2	Mapping of Crowdsourcing in Health: Systematic Review. <i>Journal of Medical Internet Research</i> , 2018, 20, e187.	4.3	100
3	Using an Alzheimer Disease Polygenic Risk Score to Predict Memory Decline in Black and White Americans Over 14 Years of Follow-up. <i>Alzheimer Disease and Associated Disorders</i> , 2016, 30, 195-202.	1.3	82
4	Jump, Hop, or Skip: Modeling Practice Effects in Studies of Determinants of Cognitive Change in Older Adults. <i>American Journal of Epidemiology</i> , 2016, 183, 302-314.	3.4	81
5	Role of Traditional Risk Factors and Antiretroviral Drugs in the Incidence of Chronic Kidney Disease, ANRS CO3 Aquitaine Cohort, France, 2004â€“2012. <i>PLoS ONE</i> , 2013, 8, e66223.	2.5	54
6	Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus. <i>Diabetes and Metabolism</i> , 2013, 39, 349-354.	2.9	46
7	CD20 Antigen May Be Expressed by Reactive or Lymphomatous Cells of Transformed Mycosis Fungoides. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1845-1854.	3.7	37
8	Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients. <i>Rheumatology</i> , 2019, 58, 401-409.	1.9	35
9	Accuracy of repeated measurements of lateâ€night salivary cortisol to screen for earlyâ€stage recurrence of <sc>C</sc>ushing's disease following pituitary surgery. <i>Clinical Endocrinology</i> , 2015, 82, 260-266.	2.4	33
10	Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs. <i>Genetics in Medicine</i> , 2015, 17, 733-738.	2.4	33
11	Association of Alzheimerâ€™s related genotypes with cognitive decline in multiple domains: results from the Three-City Dijon study. <i>Molecular Psychiatry</i> , 2015, 20, 1173-1178.	7.9	32
12	Should we consider day-2 and day-3 embryo morphology before day-5 transfer when blastocysts reach a similar good quality?. <i>Reproductive BioMedicine Online</i> , 2017, 35, 521-528.	2.4	27
13	Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing. <i>Scientific Reports</i> , 2017, 7, 6882.	3.3	24
14	A Methodologic Systematic Review of Mobile Health Behavior Change Randomized Trials. <i>American Journal of Preventive Medicine</i> , 2019, 57, 836-843.	3.0	24
15	Living network meta-analysis was feasible when considering the pace of evidence generation. <i>Journal of Clinical Epidemiology</i> , 2019, 108, 10-16.	5.0	13
16	A phase II, open-label, non-comparative study of Botulinum toxin in Restless Legs Syndrome. <i>Sleep Medicine</i> , 2012, 13, 1313-1316.	1.6	10
17	Magnetisation transfer parameters and stroke outcome. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1012-1017.	1.5	10
18	Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study. <i>BMJ Open</i> , 2017, 7, e018587.	1.9	10

#	ARTICLE	IF	CITATIONS
19	Impact of post-warming culture duration on clinical outcomes of vitrified good-quality blastocyst transfers: a prospective randomized study. <i>Fertility and Sterility</i> , 2018, 110, 1290-1297.	1.0	10
20	Postmarketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study. <i>International Journal of Cancer</i> , 2018, 142, 414-423.	5.1	9
21	Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov. <i>Genetics in Medicine</i> , 2016, 18, 796-805.	2.4	7
22	Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint Inhibitors. <i>Journal of the National Cancer Institute</i> , 2019, 111, 519-521.	6.3	7
23	Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients. <i>Aids</i> , 2013, 27, 69-80.	2.2	6
24	Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1000-1007.	4.7	4
25	Bayesian analysis from phase III trials was underused and poorly reported: a systematic review. <i>Journal of Clinical Epidemiology</i> , 2020, 123, 107-113.	5.0	4
26	Application of Basic Epidemiologic Principles and Electronic Health Records in a Deep Learning Prediction Model. <i>JAMA Dermatology</i> , 2020, 156, 472.	4.1	4
27	Impact of Biomarker-based Design Strategies on the Risk of False-Positive Findings in Targeted Therapy Evaluation. <i>Clinical Cancer Research</i> , 2018, 24, 6257-6264.	7.0	3
28	Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework. <i>JAMA Oncology</i> , 2018, 4, 1437.	7.1	3